Pharmacological evidence was also provided as inhibition of sTNF, signaling through TNFR1, reduced the accumulation of APP fragments in hippocampus and cortex of 3×Tg-AD mice, and restored synaptic dysfunction and LTP impairment in 5xFAD mice [188,189]. Here, TNFRSF1A is linked to Alzheimer disease.